ICER, advocates prep for tense meeting on Sarepta’s Duchenne drugs

Ahead of a potential FDA approval of Duchenne muscular dystrophy drugmaker Sarepta’s second treatment, drug pricing watchdog group ICER may reopen old wounds by questioning whether the company’s products help patients.